Loading...
•
Dec 31, 2024
Fulcrum Therapeutics Q4 2024 Earnings Report
Reported financial results for Q4 and full year 2024 and provided a business update.
Key Takeaways
Fulcrum Therapeutics reported its Q4 and full year 2024 financial results. They ended the year with $241.0 million in cash, cash equivalents, and marketable securities. Patient enrollment continues to progress in the Phase 1b PIONEER trial evaluating pociredir in patients with SCD.
On track to provide clinical data from the 12 mg dose cohort from the Phase 1b PIONEER trial of pociredir in SCD in mid-2025, and the 20 mg dose cohort by the end of 2025.
Ended 2024 with $241.0 million in cash, cash equivalents, and marketable securities; cash runway into at least 2027.
Patient enrollment and site activation continues to progress in the Phase 1b PIONEER trial evaluating pociredir in patients with SCD; plans to share data from the 12 mg dose cohort in mid-2025 and from the 20 mg dose cohort by the end of 2025.
Data from the Phase 3 REACH trial evaluating losmapimod in patients with Facioscapulohumeral Muscular Dystrophy will be presented on March 19th at the 2025 MDA Conference being held in Dallas, Texas.
Fulcrum Therapeutics
Fulcrum Therapeutics
Forward Guidance
Based on its current operating plans, Fulcrum continues to expect that its current cash, cash equivalents, and marketable securities will be sufficient to fund its operating requirements into at least 2027.